GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » EV-to-EBIT

180 Life Sciences (180 Life Sciences) EV-to-EBIT : -0.04 (As of May. 07, 2024)


View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 180 Life Sciences's Enterprise Value is $0.78 Mil. 180 Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.24 Mil. Therefore, 180 Life Sciences's EV-to-EBIT for today is -0.04.

The historical rank and industry rank for 180 Life Sciences's EV-to-EBIT or its related term are showing as below:

ATNF' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.72   Med: 0   Max: 1.82
Current: -0.04

During the past 5 years, the highest EV-to-EBIT of 180 Life Sciences was 1.82. The lowest was -47.72. And the median was 0.00.

ATNF's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 9.545 vs ATNF: -0.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. 180 Life Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $1.25 Mil. 180 Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.24 Mil. 180 Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1,783.35%.


180 Life Sciences EV-to-EBIT Historical Data

The historical data trend for 180 Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences EV-to-EBIT Chart

180 Life Sciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- -7.45 -6.27 -0.18 -0.06

180 Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.11 -0.09 -0.04 -0.06

Competitive Comparison of 180 Life Sciences's EV-to-EBIT

For the Biotechnology subindustry, 180 Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


180 Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 180 Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 180 Life Sciences's EV-to-EBIT falls into.



180 Life Sciences EV-to-EBIT Calculation

180 Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.784/-22.24
=-0.04

180 Life Sciences's current Enterprise Value is $0.78 Mil.
180 Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


180 Life Sciences  (NAS:ATNF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

180 Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-22.24/1.24709168
=-1,783.35 %

180 Life Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $1.25 Mil.
180 Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


180 Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


180 Life Sciences (180 Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
Executives
James N. Woody director, officer: Chief Executive Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann director 5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A. director C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu officer: COO / Chief Business Officer 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir officer: Interim CFO 2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone director C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca director 40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss director, 10 percent owner, officer: Chief Executive Officer C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold director 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard officer: Chief Scientific Officer 501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker director 290 COMMONWEALTH AVENUE #17, BOSTON MA 02115

180 Life Sciences (180 Life Sciences) Headlines

From GuruFocus

Could Insider Buying Signal that 180 Life Sciences Corp Is Undervalued?

By GuruFocus Research GuruFocus Editor 05-19-2023

180 Life Sciences Announces Presentation at the Gordon Conference

By sperokesalga sperokesalga 02-27-2023